HEIDELBERG PHARMA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.97 EUR | -1.98% |
|
-1.00% | -20.59% |
| Apr. 25 | Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
| Apr. 23 | Transcript : Heidelberg Pharma AG - Special Call |
Valuation
| Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 62.23 | 161.5 | 177 | 266.5 | 128.6 | 138.4 | - |
| Enterprise Value (EV) 1 | 52.35 | 156.7 | 171 | 266.5 | 128.6 | 138.4 | 138.4 |
| P/E ratio | -6.14 x | -8.52 x | -6.48 x | -10.8 x | -6.27 x | -9.9 x | -22.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.81 x | 16.9 x | 76.5 x | 13.4 x | 7.66 x | 12 x | 9.23 x |
| EV / Revenue | 7.81 x | 16.9 x | 76.5 x | 13.4 x | 7.66 x | 12 x | 9.23 x |
| EV / EBITDA | -6.48 x | -9.2 x | -7.13 x | -16.2 x | -6.33 x | -6.26 x | -12.8 x |
| EV / FCF | -6,579,197 x | -8,385,943 x | -6,355,429 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 3.83 x | 12.5 x | 26.4 x | - | - | - | - |
| Nbr of stocks (in thousands) | 28,158 | 31,062 | 34,173 | 46,584 | 46,600 | 46,605 | - |
| Reference price 2 | 2.210 | 5.200 | 5.180 | 5.720 | 2.760 | 2.970 | 2.970 |
| Announcement Date | 3/19/20 | 3/25/21 | 3/24/22 | 3/5/23 | 3/25/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.964 | 9.576 | 2.314 | 19.86 | 16.8 | 11.5 | 15 |
| EBITDA 1 | -9.597 | -17.55 | -24.83 | -16.42 | -20.33 | -22.1 | -10.8 |
| EBIT 1 | -10.14 | -18.28 | -25.63 | -17.18 | -21.21 | -22.6 | -11.6 |
| Operating Margin | -127.36% | -190.95% | -1,107.81% | -86.51% | -126.24% | -196.52% | -77.33% |
| Earnings before Tax (EBT) | -10.14 | -18.28 | -26.14 | -17.79 | -20.35 | - | - |
| Net income | -10.15 | -18.28 | -26.14 | -19.7 | -20.35 | - | - |
| Net margin | -127.43% | -190.95% | -1,129.76% | -99.2% | -121.1% | - | - |
| EPS 2 | -0.3600 | -0.6100 | -0.8000 | -0.5300 | -0.4400 | -0.3000 | -0.1300 |
| Free Cash Flow | -9.458 | -19.26 | -27.85 | - | - | - | - |
| FCF margin | -118.77% | -201.14% | -1,203.84% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/25/21 | 3/24/22 | 3/5/23 | 3/25/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 9.88 | 4.78 | 5.97 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -9.46 | -19.3 | -27.9 | - | - | - | - |
| ROE (net income / shareholders' equity) | -48.1% | -125% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -37.5% | - | - | - | - | - | - |
| Assets | 27.09 | - | - | - | - | - | - |
| Book Value Per Share | 0.5800 | 0.4100 | 0.2000 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 0.9 | 1.37 | 1.24 | - | - | - | - |
| Capex / Sales | 11.32% | 14.29% | 53.69% | - | - | - | - |
| Announcement Date | 3/19/20 | 3/25/21 | 3/24/22 | 3/5/23 | 3/25/24 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.97
EUR
Average target price
11.3
EUR
Spread / Average Target
+280.47%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 148M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HPHA Stock
- Financials Heidelberg Pharma AG
